Novavax (NASDAQ:NVAX) & Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis

Novavax (NASDAQ:NVAX – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Insider and Institutional Ownership

53.0% of Novavax shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Novavax and Xenetic Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax 2 2 5 0 2.33
Xenetic Biosciences 1 0 0 0 1.00

Novavax presently has a consensus target price of $13.60, indicating a potential upside of 70.85%. Given Novavax’s stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Xenetic Biosciences.

Profitability

This table compares Novavax and Xenetic Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novavax -18.64% -14.82% -7.55%
Xenetic Biosciences -123.72% -58.97% -49.54%

Risk & Volatility

Novavax has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500.

Earnings and Valuation

This table compares Novavax and Xenetic Biosciences”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $1.12 billion 1.17 $440.30 million ($0.46) -17.30
Xenetic Biosciences $2.98 million 1.26 -$2.68 million ($1.55) -1.04

Novavax has higher revenue and earnings than Xenetic Biosciences. Novavax is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Novavax beats Xenetic Biosciences on 11 of the 13 factors compared between the two stocks.

About Novavax

(Get Free Report)

Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company’s best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells. The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.